Stockscreener 앱 받기
3.90
1.30%
0.05
전일 마감가:
$3.85
열려 있는:
$3.86
하루 거래량:
58,228
Relative Volume:
0.38
시가총액:
$157.74M
수익:
$2.00M
순이익/손실:
$63.21M
주가수익비율:
2.6257
EPS:
1.4853
순현금흐름:
$-9.71M
1주 성능:
+2.09%
1개월 성능:
+11.75%
6개월 성능:
+70.31%
1년 성능:
+70.31%
1일 변동 폭
$3.86
$3.94
1주일 범위
$3.66
$3.96
52주 변동 폭
$1.975
$3.96
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
명칭
Oramed Pharmaceuticals Inc
전화
646-844-1164
주소
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Compare ORMP vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
3.90 | 155.72M | 2.00M | 63.21M | -9.71M | 1.4853 |
VRTX
Vertex Pharmaceuticals Inc
|
436.97 | 111.05B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
744.34 | 79.01B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
795.50 | 50.08B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
310.08 | 41.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
311.22 | 34.67B | 5.36B | 287.73M | 924.18M | 2.5229 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-01-12 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2022-02-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-04-20 | 개시 | Canaccord Genuity | Buy |
| 2021-02-09 | 개시 | National Securities | Buy |
| 2020-12-03 | 개시 | Alliance Global Partners | Buy |
| 2020-03-11 | 개시 | Aegis Capital | Buy |
| 2019-09-11 | 개시 | Ladenburg Thalmann | Buy |
| 2017-12-11 | 재개 | B. Riley FBR, Inc. | Buy |
| 2016-05-26 | 재확인 | FBR Capital | Outperform |
| 2015-12-01 | 재확인 | H.C. Wainwright | Buy |
| 2015-11-19 | 개시 | FBR Capital | Outperform |
| 2015-04-13 | 재개 | MLV & Co | Buy |
| 2014-01-30 | 재확인 | Aegis Capital | Buy |
| 2014-01-08 | 재확인 | Aegis Capital | Buy |
| 2014-01-08 | 개시 | MLV & Co | Buy |
| 2013-12-03 | 개시 | Aegis Capital | Buy |
모두보기
Oramed Pharmaceuticals Inc 주식(ORMP)의 최신 뉴스
Oramed Pharmaceuticals And Two Other Promising Penny Stocks For Savvy Investors - Yahoo Finance
Evolus and Oramed Pharmaceuticals Compared - National Today
Setup Watch: Is Oramed Pharmaceuticals Inc stock technically oversold2026 Opening Moves & Daily Profit Focused Stock Screening - baoquankhu1.vn
Sell Signal: What is Oramed Pharmaceuticals Incs 5 year growth outlookEarnings Overview Summary & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Fund Flows: Can Oramed Pharmaceuticals Inc keep up with sector leadersMarket Performance Summary & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Technical Analysis: Will Oramed Pharmaceuticals Inc face regulatory challenges2026 Earnings Impact & Growth Oriented Trading Recommendations - baoquankhu1.vn
Lifeward scoops US$20M after completing Oratech Pharma takeover - Mugglehead Investment Magazine
Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Passes Above 50-Day Moving AverageHere's What Happened - MarketBeat
ORMP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Oramed Pharmaceuticals stock: Oral insulin pioneer or high-risk bet? - AD HOC NEWS
ORMP Should I Buy - Intellectia AI
ORMP Stock Price, Quote & Chart | ORAMED PHARMACEUTICALS INC (NASDAQ:ORMP) - ChartMill
Oramed Completes Oratech Sale and Strategic Lifeward Financing - The Globe and Mail
ABOS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
ORMP Q4 Earnings: Beats Estimates by $1.16 - Xã Châu Thành
Oramed (ORMP) completes Oratech sale and buys $9M Lifeward notes - Stock Titan
Oramed (NASDAQ: ORMP) CSO uses 435,084 shares to cover RSU tax - Stock Titan
Oramed (NASDAQ: ORMP) CEO uses 44,818 shares to cover RSU tax withholding - Stock Titan
FOMO Trade: Is Oramed Pharmaceuticals Inc stock good for income investorsMarket Sentiment Report & Entry and Exit Point Strategies - baoquankhu1.vn
Oramed Pharmaceuticals Hits New 52-Week High of $3.76, Up 75% Yearly - Markets Mojo
Oramed Pharmaceuticals (ORMP) price target increased by 92.31% to 6.38 - MSN
Oramed Pharmaceuticals (NASDAQ:ORMP) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Oramed Pharmaceuticals: Oral Insulin Technology, Strategic Investments, and 2026 Business Overview - Minichart
Oramed: Q4 Earnings Snapshot - Barchart.com
Oramed Pharmaceuticals 2025 10-K: $2.0M Revenue, $1.50 Diluted EPS - TradingView — Track All Markets
Oramed (NASDAQ: ORMP) pivots with Lifeward deal and Alpha Tau stake - Stock Titan
Lifeward closes Oramed partnership, secures $10 million funding By Investing.com - Investing.com Australia
Tranche Update on Oramed Pharmaceuticals Inc.'s Equity Buyback Plan announced on June 26, 2024. - marketscreener.com
Lifeward Closes Oramed Partnership, Acquires Oratech Pharma - Moomoo
Lifeward closes Oramed partnership, secures $10 million funding - Investing.com
Lifeward Successfully Closes on Strategic Partnership with Oramed - manilatimes.net
Lifeward adds biotech drug-delivery tech and taps up to $47M - Stock Titan
Lifeward Ltd. completed the acquisition of Oratech Pharma, Inc. from Oramed Pharmaceuticals Inc.. - marketscreener.com
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Oramed Pharmaceuticals Inc expected to post breakeven results a shareEarnings Preview - TradingView
Surprises Report: Does Oramed Pharmaceuticals Inc stock benefit from AI growth2026 Macro Impact & Pattern Based Trade Signal System - baoquankhu1.vn
Oramed Pharmaceuticals (ORMP) to Release Earnings on Thursday - MarketBeat
Market Overview: What is Oramed Pharmaceuticals Incs 5 year growth outlookEarnings Growth Report & High Accuracy Swing Entry Alerts - baoquankhu1.vn
[Form 4] ORAMED PHARMACEUTICALS INC. Insider Trading Activity - Stock Titan
Oramed (NASDAQ: ORMP) CEO receives 167,005 RSUs vesting from 2026 - Stock Titan
Oramed (NASDAQ: ORMP) COO receives 95,889 RSUs vesting from 2026 - Stock Titan
Oramed (NASDAQ: ORMP) CFO receives 95,889 RSU equity award - Stock Titan
Oramed deal reshapes Lifeward (NASDAQ: LFWD) with new tech and funding - Stock Titan
Oral insulin and robotic exoskeletons: Lifeward’s $47M pivot - Stock Titan
Retail Trends: How sensitive is Oramed Pharmaceuticals Inc to inflationWeekly Trade Recap & Low Risk Entry Point Guides - baoquankhu1.vn
Is Oramed Pharmaceuticals Inc stock undervalued right nowEarnings Risk Report & Verified Momentum Watchlists - baoquankhu1.vn
Returns Recap: Is Oramed Pharmaceuticals Inc stock a smart retirement pickMarket Volume Report & High Yield Stock Recommendations - baoquankhu1.vn
Oramed (ORMP) CEO donates 100,000 shares to charity - Stock Titan
Lifeward shareholders approve Oramed partnership deal By Investing.com - Investing.com India
Lifeward shareholders approve Oramed partnership deal - Investing.com
Lifeward Partners with Oramed to Enhance Biotech Portfolio and Drive Path to Profitability - Quiver Quantitative
Oramed Pharmaceuticals Inc (ORMP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Oramed Pharmaceuticals Inc 주식 (ORMP) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kidron Miriam | Chief Scientific Officer |
Jan 22 '26 |
Option Exercise |
0.00 |
19,000 |
0 |
1,448,664 |
| Gabay Avraham | Chief Financial Officer |
Jan 22 '26 |
Option Exercise |
0.00 |
19,000 |
0 |
649,256 |
| KIDRON NADAV | President and CEO |
Jan 22 '26 |
Option Exercise |
0.00 |
109,000 |
0 |
3,355,238 |
1.23%
0.23%
자본화:
|
볼륨(24시간):